Antiangiogenic Therapy in Gastroesophageal Cancer

Zhaohui Jin, Harry H Yoon

Research output: Contribution to journalArticle

6 Scopus citations


Antiangiogenesis therapy is one of only 2 biologically targeted approaches shown to improve overall survival over standard of care in advanced adenocarcinoma of the stomach or gastroesophageal junction (GEJ). Therapeutic targeting of vascular endothelial growth factor receptor 2 improves overall survival in patients with previously treated advanced gastric/GEJ adenocarcinoma. No antiangiogenesis therapy has demonstrated an overall survival benefit in patients with chemo-naïve or resectable esophagogastric cancer or in patients whose tumors arise from the esophagus. Promising ongoing clinical investigations include the combination of antiangiogenesis therapy with immune checkpoint inhibition and anti-human epidermal growth factor receptor 2 therapy.

Original languageEnglish (US)
JournalHematology/Oncology Clinics of North America
StateAccepted/In press - 2017


  • Angiogenesis
  • Checkpoint inhibitor
  • Esophageal cancer
  • Gastric cancer
  • Immunotherapy

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Antiangiogenic Therapy in Gastroesophageal Cancer'. Together they form a unique fingerprint.

  • Cite this